Market News AIOpen the app

Ocugen has made a deal with Celairis Therapeutics to let them sell OCU400 in certain areas.

DealRead the original at SEC EDGAR
Good for OCGN

Ocugen gained a partner for pursuing approvals and sales, with possible fees, royalties, and a share of profits. Some payments depend on trial success and approval, and a separate supply deal is not yet signed.

OCGN · Ocugen, Inc.

AI read · Good for OCGN

The AI's read

This gives Ocugen a local partner to pursue approvals and sales, plus payments tied to OCU400’s progress. Ocugen keeps the right to make the treatment. Some payments depend on positive Phase 3 results or Australian approval. The companies also still need to work toward a separate supply deal within 90 days.

Get alerts for OCGN

Follow Ocugen, Inc. (OCGN) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for OCGN
Free on the App Store and Google Play, or on the web.